Evaluation of the artificial intelligence (AI) for predicting optimized insulin dosage in diabetic patients

Renascience Inc.0 个研究点目标入组 130 人开始时间: 待定最近更新: 2025年6月10日

适应症

试验速览

暂无简介。

•Clinical data of hospitalized type 2 diabetes patients who received insulin therapy from diabetologists will be collected, provided they meet all the following eligibility criteria and do not fall under any exclusion criteria.
•Eligibility Criteria:
•(1) Patients using ultra-rapid-acting insulin and long-acting insulin (insulin glargine, insulin degludec)
•(2) Patients aged 20 years or older
•(3) Patients who have provided written consent to participate in the study
•(4) Patients with a hospital stay of 7 days or more

•(1) Patients who are pregnant or may be pregnant
•(2) Patients with or suspected of having diabetic gastroparesis
•(3) Patients with severe diabetic autonomic neuropathy
•(4) Patients with pre-proliferative diabetic retinopathy or proliferative diabetic retinopathy, or suspected of having these conditions
•(5) Patients undergoing continuous subcutaneous insulin infusion therapy or continuous intravenous insulin infusion
•(6) Patients who have not been discharged since undergoing general anesthesia surgery
•(7) Patients with missing data in the specified input data without any reason such as tests
•(8) Patients whose primary purpose is not blood glucose control
•(9) For cases from Tohoku University Hospital, data from hospitalizations before 2021 (as these data may have been used for the training of the experimental device)

Correct rate

Rate when the difference between the test device and the units prescribed by diabetologists is within the acceptable range.

未报告次要终点

发起方